J&J Bows Out of Race for Pfizer's $20B Consumer Health Biz Post author:Sam Post published:January 25, 2018 Post category:BioPharma Now insiders say J&J has decided it is no longer interested. Source: BioSpace You Might Also Like Pfizer Quietly Kills 3 Pipeline Programs January 30, 2017 Carmat Expands Its PIVOTAL Study Internationally, In Line With Its Clinical Strategy And CE Marking Process October 5, 2017 Vertex Quietly Terminates a Small Phase II CF Trial September 11, 2017
Carmat Expands Its PIVOTAL Study Internationally, In Line With Its Clinical Strategy And CE Marking Process October 5, 2017
